TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03552835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal upto firm dentin
Description: occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
Study: NCT00642681

Intervention type: DRUG
Intervention: Technosphere Insulin
Description: Technosphere® Insulin (TI) Inhalation Powder, prandial
Study: NCT01600430

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
Study: NCT01989572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyrosinase Peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyrosinase Peptide
Description: Given SC
Study: NCT03309904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Control training program
Description: 10-minute training program to be performed at all team training sessions during the season.
Study: NCT01673490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride/Tamsulosin
Description: 0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
Study: NCT00760045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Guar Galactomannan
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Study: NCT02013011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only
Description: application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only
Description: application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
Study: NCT00271154

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
Description: All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
Description: All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
Study: NCT00782574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Tablets Oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV every 3 weeks
Study: NCT00760045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Guar Galactomannan
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl Guar Galactomannan
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Study: NCT01269177

Intervention type: DEVICE
Intervention: Non invasive ventilation
Description: Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability
Study: NCT01106391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordis AAA stent graft system INCRAFT TM
Study: NCT04220710

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction and methylation detection
Description: DNA extraction and methylation detection

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction and methylation detection
Description: DNA extraction and methylation detection
Study: NCT01823757

Intervention type: OTHER
Intervention: Pharmaceutical care
Description: pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
Study: NCT01858597

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biachemical detection
Description: Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biachemical detection
Description: Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed.
Study: NCT02062476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Study: NCT06260072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium and riboflavin supplement
Description: Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: magnesium and riboflavin supplement
Description: Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
Study: NCT00965549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
Study: NCT03534791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Personalized email which will aim for reminding of the translator about the PLSs on hold.
Study: NCT01721629

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sudden wean of nasal CPAP

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gradual wean of nasal CPAP
Study: NCT02338856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066 200mg
Description: 100mg bid (multiple dose, day 8)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg bid (multiple dose, day 8)
Study: NCT01316939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: GSK1605786A 500 milligrams once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00777036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT01523457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: * Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: * Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.
Study: NCT04249544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 1mg of pramipexole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 1mg of pramipexole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 1mg of pramipexole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 1mg of pramipexole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1mg equivalent of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1mg equivalent of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1mg equivalent of placebo
Study: NCT01316939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: GSK1605786A 500 milligrams twice daily
Study: NCT04249544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1mg equivalent of placebo
Study: NCT06455007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis 3x10 drops (7 days)
Study: NCT01010269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Complete Knee
Description: Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard High Flex RP
Description: Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
Study: NCT00899678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: 400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab Pegol
Description: 200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
Study: NCT02345044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Study: NCT00758407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate hydrochloride
Description: sustained release, dosage according to an individual titration schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage according to an individual titration schedule
Study: NCT00676156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral lipoic acid (LA)
Description: A single 1200 mg dose of oral LA will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipoic acid (LA) with fish oil and LA without fish oil
Description: Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R lipoic acid
Description: A single oral dose of 1200mg R enantiomer LA will be administered.
Study: NCT00223912

Intervention type: DEVICE
Group type: OTHER
Intervention: ERGYS BikeFunctional Electrical Stimulation Ergometry
Description: A
Study: NCT04379323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: YuWell YE900 Electronic Sphygmomanometer
Description: Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
Study: NCT02758041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sebacia Microparticles
Study: NCT00132158

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan (Camptosar), Gefitinib (Iressa)
Description: See Detailed Description for treatment plan.
Study: NCT01337518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-4176
Description: EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
Study: NCT02665468

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supported adoption intervention
Description: An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator control
Description: The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
Study: NCT03481504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy-Exposure and Perspective Taking
Description: To increase patients' participation by improving their level of coping with chronic pain.
Study: NCT00768768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrokinetic Transungual System (ETS) - Terbinafine Gel
Description: Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ETS-Terbinafine Gel
Description: Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ETS-Terbinafine Gel
Description: Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ETS-Terbinafine Gel
Description: Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ETS-Terbinafine Gel
Description: Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min
Study: NCT01361880

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reduce Infant Mortality
Description: The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
Study: NCT00439725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to placebo will receive a matching placebo tablet once daily.
Study: NCT02366247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Tα1
Description: 3.2mg/ml, once a week, taken subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match PEG-Tα1
Description: 1ml, once a week, taken subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks
Study: NCT02565953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-releasing PTA balloon catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA balloon catheter
Study: NCT02150460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-site peribulbar injection
Description: injection into the inferior medial orbital compartment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two- site peribulbar injection
Description: Two injections into the infero-temporal and supero-nasal orbital compartments
Study: NCT04826120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCEA Infusion
Description: Patients of this group Had PCEA during the second stage of labor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion
Description: Patients of this group Had continuous epidural infusion during the second stage of labor
Study: NCT00185172

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo oral tablets for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil oral tablets for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets
Description: olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets